A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Clinical trial NCT06290141 · RECRUITING
Trial details
- NCT number
- NCT06290141
- Sponsor
- Sanofi
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-21
- Primary completion
- 2027-07-09
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.